Skip to main content
main-content

01.11.2015 | Original Article - Health Services Research | Ausgabe 11/2015

Rheumatology International 11/2015

Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study

Zeitschrift:
Rheumatology International > Ausgabe 11/2015
Autoren:
Iván Ferraz-Amaro, Daniel Seoane-Mato, Fernando Sánchez-Alonso, María A. Martín-Martínez, emAR II Study Group
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00296-015-3363-5) contains supplementary material, which is available to authorized users.
Please see the Appendix section emAR II study group members.

Abstract

The objective of this study was to describe the variability in the prescription of csDMARDs for the treatment of RA between centers in Spain and to explore how this variability relates to demographic, disease, physician, and institutional characteristics. A cross-sectional nationwide study was carried out to examine data from 1352 patients. Multilevel logistic regression with two levels was performed to assess the relationships between individual and disease-related factors, as well as physician and hospital characteristics, vis-à-vis csDMARD prescription. Having three or more comorbidities (OR 0.353 [0.173–0.721]), disease duration (OR 0.321 [0.174–0.595]), and the existence of an early-arthritis unit (OR 0.552 [0.335–0.910]) were negatively associated with the prescription of one csDMARD versus nonprescription; contrary, the presence of rheumatoid factor (OR 1.909, 95 % CI [1.181–3.086]) was positively associated. On the other hand, while corticoid intake (OR 1.561 [1.088–2.240]), the maximum number of painful joints, and the presence of nursing consultation (OR 1.626 [1.078–2.452]) were positively associated with the prescription of multiple csDMARDs versus one csDMARD, patient’s age (OR 0.984 [0.974–0.995]) and disease duration (OR 0.669 [0.462–0.968]) were negatively associated. Despite all these, variability in the prescription of csDMARDs between hospitals remained statistically significant after adjusting for these individual and hospital characteristics. Within the emAR II study, there was a marked variation in the number of csDMARDs prescribed between hospitals. The reasons for these variations remain unclear and cannot be solely related to disease or center characteristics.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Nur für berechtigte Nutzer zugänglich
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2015

Rheumatology International 11/2015 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise